Tag Archives: ReNeuron

Some biotech investors had probably never heard of exosomes until Codiak’s chief executive, Doug Williams, made his pitch at the JP Morgan conference two weeks ago. But the area has been gaining traction, and Jazz’s $56m up-front...

ReNeuron Group plc, a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it is the lead industry participant in a new grant award from the Welsh Government to advance its emerging exosome therapy platform. ...

Data show that ExoPr0 can inhibit proliferation in a diverse panel of cancer cell lines ReNeuron Group plc, a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it will today be presenting further new positive ...

Based upon these promising findings, ReNeuron is pursuing pre-clinical development of its selected exosome nanomedicine candidate, designated ExoPr0, targeting GBM.  ReNeuron Group Plc has selected glioblastoma multiforme, the most common form of brain cancer, as the first clinical target for its ...

On January 11, 2016, the ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy development company, announced that it has been awarded a £2.1 million (just over $3 million) grant from Innovate UK to further advance the company’s ...

Exosomes are small (30–100 nm) membrane vesicles secreted by a variety of cell types and only recently have emerged as a new avenue for cell-to-cell communication. They are natural shuttles of RNA and protein cargo, making them attractive as potential ...

LONDON (Alliance News) – Stem-cell therapy development company ReNeuron Group PLC Tuesday said data related to its exosome nanomedicine platform has been published in peer-reviewed scientific journal PLOS ONE. The UK-based company is researching the “therapeutic potential of exosomes derived ...

from Reuters Clinical stage stem cell specialist Reneuron has announced it has raised £68.4m in what it claims is the largest funding round undertaken in the cell therapy sector globally this year. The firm, which is relocating from Guildford to ...

Guildford, UK, 1 April 2015: ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy company, today announces a number of Board and senior management changes as the Company prepares for its next phase of development. The changes announced ...

from Proactive Investors by Giles Gwinnett Stem cell specialist ReNeuron (LON:RENE) says it’s upbeat after what it called a ‘transformational’ year, as it posted results for the year to end March. A share placing in July raised £25.3mln bolstering the ...